文献速递骨质疏松与钙磷/甲状旁腺

唑来膦酸减少原发性和继发性骨骼脆性青少年骨折的临床疗效

Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项在学术医疗中心开展的回顾性队列研究纳入102例0至21岁原发性或继发性骨骼脆性患者,2010至2017年接受唑来膦酸治疗。中位治疗1.8年后,总体年化骨折率从0.6次/年降至0次/年(P<.001),原发性和继发性骨骼脆性组均显著降低。

要点

  • 唑来膦酸治疗与骨骼脆性儿童和年轻成人年化骨折率显著下降相关。
  • 总体年化骨折率中位数从0.6次/年降至0次/年(P<.001)。
  • 原发性和继发性骨骼脆性组的骨折率均显著降低(P均<.001)。

核心结论

  • 作为临床诊疗的一部分,唑来膦酸治疗与该儿童和年轻成人骨骼脆性队列的年化骨折率显著下降相关。

研究设计与样本

  • 回顾性队列研究,在学术医疗中心开展,纳入102例(65例男性;39例原发性骨骼脆性,63例继发性骨骼脆性)0至21岁、2010至2017年间因骨骼脆性接受唑来膦酸治疗的患者。
  • 唑来膦酸由治疗临床医生根据标准化方案酌情处方。
  • 主要结局为年化骨折率变化,次要结局包括长骨和脊柱骨折率;在部分有双能X线吸收测定(DXA)扫描的个体中分析面积骨密度。

主要发现

  • 在中位治疗时长1.8年(IQR 0.6-3.0)内,总体年化骨折率中位数从0.6次/年(IQR 0.3-1.1)降至0次/年(IQR 0-0.4),P<.001。
  • 原发性骨骼脆性组年化骨折率从1.0次/年(IQR 0.6-1.5)降至0.3次/年(IQR 0-0.6),P<.001。
  • 继发性骨骼脆性组年化骨折率从0.5次/年(IQR 0.1-0.8)降至0次/年(IQR 0-0.3),P<.001。
  • 当仅限长骨骨折或长骨加脊柱骨折时,骨折率的显著降低持续存在。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prior studies have demonstrated the safety and efficacy of zoledronic acid (ZA) to increase bone mineral density (BMD) in children. By contrast, the efficacy of ZA on fractures in the pediatric population remains uncertain. OBJECTIVE: To investigate the effect of ZA on fracture rate in a clinical cohort of children and young adults with skeletal fragility. METHODS: This retrospective cohort study, conducted at an academic medical center, included 102 individuals (65 male; 39 with primary and 63 with secondary skeletal fragility), aged 0 to 21 years, treated with ZA for skeletal fragility between 2010 and 2017. ZA was prescribed at discretion of the treating clinician using a standardized protocol. The primary outcome was change in annualized fracture rate. Secondary outcomes included long bone and spine fracture rates. Areal BMD was analyzed in a subset of individuals with dual energy x-ray absorptiometry (DXA) scans. RESULTS: The overall median fracture rate decreased from 0.6 (IQR 0.3-1.1) to 0 (IQR 0-0.4) fractures per year, P < .001, over a median treatment duration of 1.8 (IQR 0.6-3.0) years. Significant reductions in fracture rate were observed in both primary (1.0 [IQR 0.6-1.5] to 0.3 [IQR 0-0.6]) and secondary (0.5 [IQR 0.1-0.8] to 0 [IQR 0-0.3]) forms of skeletal fragility, P < .001 for both. Significant reductions in fracture rate persisted when limited to long bone or long bone plus spine fractures. CONCLUSION: ZA treatment as a component of clinical care was associated with significant declines in fracture rate in this cohort of children and young adults with skeletal fragility.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Stoffers AJ, Mancilla EE, Levine MA, et al. Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility. J Clin Endocrinol Metab. 2025. PMID: 39324646. doi:10.1210/clinem/dgae661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。